A Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong
|
|
- Brandon Powell
- 5 years ago
- Views:
Transcription
1 A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong
2 Outline The pathogenesis of Late life cognitive impairment A framework of care
3 The golden age.. Age (Cambridge dictionary) The period of time someone has been alive The Life Cycle Course of developmental changes from inception as fertilized zygote to a mature reproductive state, followed by subsequent decline
4 At 85 years old, you may experience Reduced motility Reduced interests Forgetfulness Repetitiveness Mini-mental state exam 24/30 Delayed recall 2/10 1 minute animal fluency test 10 examplars
5 Brain Imaging Serial MRI brain scans, taken six months apart, show progression from mild cognitive impairment to Alzheimer's disease, with significant atrophy (blue) and ventricle enlargement (orange/red). (University of California, San Diego, UCSD)
6 Brain Imaging Klunk, W.E., et al., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology, 2004;55:306-19
7 Alzheimer s disease
8 Alzheimer Disease Anatomical diagnosis of Auguste Deter Cerebral atrophy Arteriosclerosis of small blood vessels Presentation by Alzheimer at conference in Tubingen (1906) Fibrils with characteristics thickness (tangles) Small miliary foci (plaques)
9 Amyloid protein leads to AD. The Amyloid Cascade Hypothesis Amyloid Precursor Protein Aß plaques Aß Aß oligomer Aß Fibrils P-Tau Excitotoxicity Inflammation Oxidation Mitochondrial dysfunction Neurofibrillary tangles Synapse failure, Cell Death Cummings, Alz Dement, 2011
10 How does Alzheimer s disease develop?
11 A life course approach AGE Dementia Alzheimer disease
12 At conception Early onset AD Amyloid precursor gene (21) Presenilin 1 gene (14) Presenilin 2 gene (1) Late onset AD Apolipoprotein E gene (19) Gene dose effects Advance age of onset >200 genes identified Inflammatory pathway, energy metabolism, neuronal repair, estrogen, immune response Tanzi et al., Nature, 1987;329(6135): ; Lewy-Lahad et al., Science 1995;269: ; Sherrington et al., Nature, 1995;375 (6534): ; Corder et al., Science 1993;261(5123):
13 Early Life Environmental Enrichment Transgenic and wild type mice were either housed under standard conditions or in an enriched environment. Standard housed Transgenic mice Diminished hippocampal cell proliferation Reduced number of mature newborn neurons. Environmental enrichment reversed this genotype effect. Cognitive and physical stimulation Increasing the number of newborn mature hippocampal neurons in transgenic mice. Herring A, Exp Neurol. 2009;216:
14 A life course approach Dementia Alzheimer disease
15 Education High education is a protective factor for the development of dementia. Enhanced cognitive reserve? Higher education delay the onset of decline. Modulate clinical manifestations of disease burden? Valenzuela & Sachdev, Psychol Med, 2006; Wilson et al., Arch Gen Psy, 2007; Rosell F et al., Clin Neurol Neurosurg; Hall CD et al., Neurology, 2007;
16 Education, the brain and Dementia Population-based cohort studies (Epidemiological Clinicopathological Studies in Europe; EClipSE) 3 population-based studies that included 827 post-mortem brain donation and Longer years in education at early life were associated Decreased dementia risk and greater brain weight No relationship to neurodegeneration. EclipSE Collaborative Members, Brayne C, et al. Brain 2010; 133:2210-6
17 A life course approach Dementia Alzheimer disease
18 Early Linguistic Ability - The Nun Study A longitudinal study on aging and disability using antemortem and postmortem data collected from 678 older School Sisters of Notre Dame since The causes and prevention of Alzheimer's disease, The mental and physical disability associated with old age. Healthy Aging versus dementia AD pathology Stroke Early linguistic ability Education Snowdon. et al., JAMA. 1997;277: ; Tyas et al., Age Ageing. 2007;36:
19 Occupation In a religious order study of 517 Bavarian school sisters, risk of dementia was associated with Low education (OR 4.5, 95%CI ) Not having vocational training (OR 9.1, 95% CI ) Never been appointed to a leading position (OR 3.7, 95% CI ) Bickel & Kurz, Dement Geriatr Cogn Disord, 2009;27:
20 A life course approach Dementia Alzheimer disease
21 Mid Life Body Mass Index and AD In a meta analysis Low BMI, increased risk of AD (OR 1.96, 95% CI: ) Overweight BMI, increased risk of AD (OR 1.35, ), VaD (OR 1.26, ) U-shape curve Anstev et al, Obse Rev 2011;12:e426-37
22 Atherosclerosis and dementia Rotterdam study A population based cohort of over 6600 subjects followed up with a mean of 9 years. Atherosclerosis, especially carotid plaques, are associated with an increased risk for dementia. Van Oijen et al, Ann Neurology, 2007;
23 Cognitive activities & cognitive function Cognitive activities (reading, playing board games, musical instruments, dancing) dementia risk Late life cognitive activities delayed onset of accelerated memory decline more rapid decline after onset. Stimulating leisure activities dementia risk and AD over a 4 year period in the Three-City Study in France. Midlife cognitive activity, but not physical activity, modulated risk of dementia in monzygotic twins pairs. Verghese et al., NEJM, 2003; Hall et al., Neurology, 2009; Akbaraly et al., Neurology, 2009; Carlson et al., 2008.
24 Physical activities & cognitive function Leisure time physical activity lower mortality in a US national cohort. A 24-week home based physical activity intervention provided a modest improvement in cognition over an 18-month followup period. 6 months aerobic exercise associated sex-specific effects on cognition, glucose metabolism and hypothalamic- pituitary adrenal axis. 12 months resistance training improved executive function (Stroop test) over balance and toning. Lautenschlager et al., JAMA, 2008; Gillum & Obisesan, 2010, Ann Epidemiol, 2010; Baker et al., Arch Neurol., 2010; Liu-Ambrose et al., Arch Intern Med., 2010.
25 A life course approach Dementia Alzheimer disease
26 Amyloid ß deposition in clinical normal elders Aβ deposition in cognitively normal elders is Age-related Associated with cortical thinning Hippocampal atrophy, Aβ deposition in temporal neocortex are associated with episodic memory loss in pre-dementia stage Becker et al, Ann Neurol, 2011;69: Chetelat et al., Brain 2011;134:
27 Vascular lesions in AD brains Vascular lesions Major infarcts, lacunes, microbleeds, white matter degeneration Mixed with AD pathology Synergistic effects on clinical symptoms & disease course Jellinger. J Alz Dis., 2008;14:
28 What determines the development of AD?
29 Sperling et al, Alz Dementia; 2011
30 Hypothetical Model of AD Pathophysiological Cascade Jack CR Jr. et al, Lancet Neurol, 2010
31 A framework of care From prevention to treatment A personalized approach
32 Primary Prevention From Early to Adult Life AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Perinatal Care Health Care in early life School Education Social and Leisure enrichment Occupation Safety Substance misuse
33 Primary Prevention From Mid Life AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing cardiovascular and brain health Vascular risks Depression Physical exercise Cognitive activities Social network and support Diet
34 At Late Life Preclinical & Prodromal Phase AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing cardiovascular and brain health Vascular risks Depression Physical exercise Cognitive activities Social network and support Diet Structured approach to intervention?
35 A personalized approach to dementia care Risk assessment Genetic Physical Health Cognitive reserve Early biomarker changes Intervention Stage dependent Modality Constitutional factors (Pharmacogenetics)
36 Alzheimer s disease Mild AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing physical Health Caregiver involvement Cognitive and functional maintenance Acetylcholine esterase inhibitors Functional training for IADL
37 Alzheimer s disease Moderate AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing physical Health Caregiver involvement Cognitive and functional maintenance Acetylcholine esterase inhibitors/ NMDA receptor antagonist Management of neuropsychiatric symptoms Functional training for BADL Consideration for day training
38 Alzheimer s disease Severe AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing physical Health Caregiver involvement Acetylcholine esterase inhibitors/ NMDA receptor antagonist Management of neuropsychiatric symptoms Support for BADL and physiological function Consideration for long term care
39 Dynamic model A patient Journey Preclinical Prodromal Clinical Enhancing Cognitive Reserve Attention to brain health Optimizing cognition Reduce psychiatric and physical morbidity Community Health care services Outpatients Hospitals Long term care
40 To tackle late life cognitive impairment.. Never too early Avoids being too late
41 Thank you
DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationTGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci
Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection
More informationThe Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults
The Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults. Introduction Glucose intolerance is common in older individuals and this metabolic
More informationThe role of the vascular system in dementia
The role of the vascular system in dementia James AR Nicoll Professor of Neuropathology, University of Southampton Consultant Neuropathologist, Southampton General Hospital What does the vascular system
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationBrain Health and Risk Factors for Dementia
Welcome To Brain Health and Risk Factors for Dementia Presented by Kamal Masaki, MD Professor and Chair Department of Geriatric Medicine John A. Burns School of Medicine, UH Manoa April 4, 2018 10:00 11:00
More informationThe Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging
The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationWHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationCognitive ageing and dementia: The Whitehall II Study
Cognitive ageing and dementia: The Whitehall II Study Archana SINGH-MANOUX NIH: R01AG013196; R01AG034454; R01AG056477 MRC: K013351, MR/R024227 BHF: RG/13/2/30098 H2020: #643576 #633666 Outline Lifecourse
More informationMETABOLIC SYNDROME, NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT: STATE OF LEVEL OUTPATIENT CLINIC IN ITALY
METABOLIC SYNDROME, NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT: STATE OF THE ART AND DATA FROM A SECOND LEVEL OUTPATIENT CLINIC IN ITALY Valeria Calsolaro Post graduating school on Geriatric medicine University
More informationType 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky
Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationDepression: An Important Risk Factor for Cognitive Decline
Depression: An Important Risk Factor for Cognitive Decline No conflicts of interest Sarah K. Tighe, M.D. Assistant Professor University of Iowa Carver College of Medicine Department of Psychiatry Institute
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More information#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationAT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE
AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology Mary Quiceno, MD discloses she has received honoraria
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationRisk Factor Reduction and Dementia Prevalence Deborah E. Barnes, PhD, MPH
Risk Factor Reduction and Dementia Prevalence Deborah E. Barnes, PhD, MPH Associate Professor Psychiatry and Epidemiology & Biostatistics University of California, San Francisco San Francisco VA Medical
More informationSilent Cerebral Strokes: Clinical Outcomes and Management
Silent Cerebral Strokes: Clinical Outcomes and Management Nagaendran Kandiah Senior Consultant Neurologist, National Neuroscience Institute, Singapore Clinician Scientist, National Medical Research Council,
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationPrevention, health promotion & early intervention in dementia
Prevention, health promotion & early intervention in dementia Alzheimer New Zealand Conference 2014 Steve Iliffe Professor of Primary Care & Older People University College London Rotorua, New Zealand
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationUNIVERSITY OF CALGARY. Predicting Cognitive Decline in Patients with TIA and Minor Stroke. Muhammad Amlish Munir A THESIS
UNIVERSITY OF CALGARY Predicting Cognitive Decline in Patients with TIA and Minor Stroke by Muhammad Amlish Munir A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILMENT OF THE REQUIREMENTS
More informationJohnson, V. E., and Stewart, W. (2015) Traumatic brain injury: Age at injury influences dementia risk after TBI. Nature Reviews Neurology, 11(3), pp. 128-130. (doi:10.1038/nrneurol.2014.241) There may
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationDelirium, Apo-E status, and AD CSF biomarkers
Delirium, Apo-E status, and AD CSF biomarkers Zhongcong Xie, M.D., Ph.D. Geriatric Anesthesia Research Unit Department of Anesthesia, Critical Care and Pain Medicine Massachusetts General Hospital Harvard
More informationUNIVERSITY OF WESTERN ONTARIO
UNIVERSITY OF WESTERN ONTARIO Vladimir Hachinski, CM, MD, FRCPC, DSc Department of Clinical Neurological Sciences University of Western Ontario London, Ontario, Canada Vladimir.hachinski@lhsc.on.ca ALZHEIMER
More informationDementia is not normal aging!
The Future of Alzheimer s Disease Treatment Adam L. Boxer, MD, PhD Director, Alzheimer s Disease Clinical Trials Program Memory and Aging Center Assistant Professor of Neurology University of California,
More informationOutline of Lecture 2/13/2018
Allan I. Pack, M.B.Ch.B., Ph.D., FRCP John Miclot Professor of Medicine Director, Center for sleep and Circadian Neurobiology University of Pennsylvania Perelman School of Medicine Philadelphia, Pennsylvania
More informationPost Stroke Cognitive Decline
Post Stroke Cognitive Decline Deborah A. Levine, MD, MPH Departments of Medicine & Neurology University of Michigan deblevin@umich.edu Presenter Disclosure Information Deborah A. Levine, MD, MPH Post Stroke
More informationTherapeutic Benefits of Caregiver Interventions
Therapeutic Benefits of Caregiver Interventions Laura N. Gitlin, Ph.D. Professor, Department Community Public Health, School of Nursing Director, Center for Innovative Care in Aging Johns Hopkins University
More informationVascular and Degenerative Causes of Cognitive Impairment: How are they linked?
Vascular and Degenerative Causes of Cognitive Impairment: How are they linked? MCI Symposium, Public Education Forum Presented by: Rebecca Gottesman, MD PhD January 20, 2019 1 Disclosures I am an Associate
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationProbable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies
Case Report Taiwanese Journal of Psychiatry (Taipei) Vol. 25 No. 1 2011 45 Probable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies Sin-Yi Chen, M.D. 1, Yuan-Han
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationMild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD
AD is a Neurodegenerative Disease as Seen in the PET Scan and is Characterized by Amyloid Plaques and Neurofibrillary Tangles Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for
More informationRESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH
EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationMemory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging
Standard Deviations from Mean Memory Matters: Preventing and Treating Late-Life, Cognitive Decline Daniel L. Murman, MD, MS Director, Behavioral and Geriatric Neurology Program Professor & Vice Chair,
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationFlicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease
Flicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease Mojtaba Golzan (Research Fellow-Alzheimer s Australia) Department of Clinical Medicine, Macquarie University Ms. Dana Georgevsky
More informationAlzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS)
Alzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS) AN OVERVIEW (with material provided by Ben Handen & Nicole Schupf) https://www.nia.nih.gov/research/abc-ds Alzheimer s Biomarkers Consortium
More informationTheme Topics Subtopics. Basic and Translational Science. Development of New Models and Analysis Methods
Basic and Translational Science Development of New Models and Analysis Methods α-synuclein Amyloid/Abeta Behavioral models Inflammation Novel assays and technologies Screening studies/platforms Seeding
More informationYin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre
Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5
More informationKA Toulis, K. Dovas, M. Tsolaki. The endocrine facets of Alzheimer s disease and dementia-related disorders
KA Toulis, K. Dovas, M. Tsolaki The endocrine facets of Alzheimer s disease and dementia-related disorders Sex hormones Calcium metabolism GH/IGF-I Thyroid axis Metabolic hormones + dementia Sex hormones
More informationObjective 4/22/2019. Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation.
Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation Dereck Salisbury, PhD Assistant Professor, Clinical Exercise Physiologist Director: Laboratory
More informationInteraction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation
Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation Dereck Salisbury, PhD Assistant Professor, Clinical Exercise Physiologist Director: Laboratory
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationRound table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation
Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation 1. Reflection of Mild Cognitive Impairment (MCI) and Dementias by Molecular Imaging, PET
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a postprint version which may differ from the publisher's version. For additional information about this
More informationMary Sano, PhD Mount Sinai School of Medicine James J Peters Veterans Affairs Hospital June 15, 2013
Preventing and Treating Alzheimer's Disease: Recruiting Patients for Clinical Trials Mary Sano, PhD Mount Sinai School of Medicine James J Peters Veterans Affairs Hospital June 15, 2013 Goals and Learning
More informationDiabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian
Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationNeuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia
86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile
More informationSynaptic changes in dementia: links to cognition and behaviour
Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research Agenda Discuss synaptic changes in various dementias
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationALZHEIMER S DISEASE FACTOIDS & STATISTICS
ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10
More informationBGS Spring Risk Factors and Preventative Strategies for Dementia
Risk Factors and Preventative Strategies for Dementia Dr Blossom Stephan Senior Lecturer (in Risk Prediction) Newcastle University Institute for Ageing and Institute of Health and Society BGS Spring Meeting
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationPOST STROKE DEMENTIA: DIAGNOSIS & INTERVENTION. Danielle E. Eagan, Ph.D. Barrow Neurological Institute Stroke Symposium October 13, 2018
POST STROKE DEMENTIA: DIAGNOSIS & INTERVENTION Danielle E. Eagan, Ph.D. Barrow Neurological Institute Stroke Symposium October 13, 2018 Overview Stroke & Cognitive Impairment The VCI continuum & terminology
More informationDementia and Alzheimer s disease
Since 1960 Medicine Korat โรงพยาบาลมหาราชนครราชส มา Dementia and Alzheimer s disease Concise Reviews PAWUT MEKAWICHAI MD DEPARTMENT of MEDICINE MAHARAT NAKHON RATCHASIMA HOSPITAL 1 Prevalence Increase
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationEvidence-Based Treatments and Community Resources for Persons with Memory Loss. Prevention vs. Treatment
Evidence-Based Treatments and Community Resources for Persons with Memory Loss Presented by: Sandy C. Burgener, Ph.D., R.N., FAAN Associate Professor Emerita University of Illinois College of Nursing Adjunct
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2013 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader June 2013 The Australian Imaging Biomarkers
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationCognitive Reserve In Alzheimer s Disease: Implications for Detection and Prevention
Cognitive Reserve In Alzheimer s Disease: Implications for Detection and Prevention MATTHEW J. BEELEN, M.D. Program Director, Geriatric Medicine Fellowship Department of Family and Community Medicine Lancaster
More informationCASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?
CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.
More informationNext patient please Dementia Clare Hawley 2018
Next patient please Dementia Clare Hawley 2018 I have no conflict of interest to declare Dr Clare Hawley Associate Specialist Cardiology Chesterfield Royal Hospital GPwSI Refractory Angina Hon Clinical
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationMEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH
MEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH Nicci Kobritz, President Center for Brain Health & Youthful Aging Home Health 1 Our Goal Reduce the impact of modifiable medical risk factors associated
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationSelf-Compassion in Taking & Giving Care. Objectives
Self-Compassion in Taking & Giving Care Tiffany Chow, MD, MSc, FAAN Senior Scientist, Baycrest Health Sciences Associate Professor, University of Toronto Neurology and Geriatric Psychiatry Objectives Is
More informationAlzheimer s Disease Centers meeting San Diego, CA October 14, NIA-Division of Neurosciences update"
Alzheimer s Disease Centers meeting San Diego, CA October 14, 2017 NIA-Division of Neurosciences update" Eliezer Masliah, M.D. Director, Division of Neuroscience, National Institute on Aging, NIH AD grants
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More information